PMID- 27456710
OWN - NLM
STAT- MEDLINE
DCOM- 20171116
LR  - 20210109
IS  - 2045-7634 (Electronic)
IS  - 2045-7634 (Linking)
VI  - 5
IP  - 9
DP  - 2016 Sep
TI  - Do androgen deprivation and the biologically equivalent dose matter in 
      low-dose-rate brachytherapy for intermediate-risk prostate cancer?
PG  - 2314-22
LID - 10.1002/cam4.820 [doi]
AB  - The objective of this study was to investigate the impact of the biologically 
      equivalent dose (BED) on treatment outcomes after iodine-125 low-dose-rate 
      brachytherapy (LDR-BT) with or without supplemental external beam radiotherapy 
      (EBRT) and androgen deprivation therapy (ADT) for intermediate-risk prostate 
      cancer (PCa). We retrospectively evaluated 292 Japanese patients. The impact of 
      the BED and ADT on treatment outcomes was investigated. Cox proportional hazard 
      models were used for univariate and multivariate analysis with biological 
      progression-free survival (bPFS) and clinical progression-free survival (cPFS) as 
      the primary outcome measures. The median follow-up was 66 months. The bPFS and 
      cPFS rates at 5-/7-years were 91.6/87.7% and 95.9/94.0%, respectively. When 
      stratified by BED levels, the bPFS rates at 5-/7-years were 92.1/89.3% for 
      <178.0 Gy2, and 91.2/86.0% for >/=178.0 Gy2 , respectively (P > 0.05). Based on ADT 
      duration, the bPFS rates at 5-/7-years were 89.8/83.5%, 89.7/89.7%, and 
      97.5/97.5% for none, 1-3 months, and 4-12 months, respectively (P = 0.03). For 
      the univariate analysis, the use of ADT and its duration were significant 
      predictors for bPFS, whereas BED was not significant. A multivariate analysis did 
      not indicate the use of ADT itself was significant, however, when covariates were 
      accounted for by the duration of ADT, the longer use of ADT was found to 
      significantly improve bPFS. Although cPFS was associated neither with the BED 
      levels nor ADT duration (P > 0.05), ADT duration had a trend of improving cPFS 
      (P = 0.053). The higher levels of BED did not significantly impact bPFS for 
      intermediate-risk PCa after LDR-BT with or without supplemental EBRT and ADT. The 
      longer duration of ADT could provide an additional benefit in the context of 
      high-dose irradiation generated by LDR-BT.
CI  - (c) 2016 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
FAU - Tabata, Ryuji
AU  - Tabata R
AD  - Department of Urology, Jikei University School of Medicine, Tokyo, Japan. 
      tabata2125@gmail.com.
FAU - Kimura, Takahiro
AU  - Kimura T
AD  - Department of Urology, Jikei University School of Medicine, Tokyo, Japan.
FAU - Kuruma, Hidetoshi
AU  - Kuruma H
AD  - Department of Urology, Jikei University School of Medicine, Tokyo, Japan.
FAU - Sasaki, Hiroshi
AU  - Sasaki H
AD  - Department of Urology, Jikei University School of Medicine, Tokyo, Japan.
FAU - Kido, Masahito
AU  - Kido M
AD  - Department of Urology, Jikei University School of Medicine, Tokyo, Japan.
FAU - Miki, Kenta
AU  - Miki K
AD  - Department of Urology, Jikei University School of Medicine, Tokyo, Japan.
FAU - Takahashi, Hiroyuki
AU  - Takahashi H
AD  - Department of Pathology, Jikei University School of Medicine, Tokyo, Japan.
FAU - Aoki, Manabu
AU  - Aoki M
AD  - Department of Radiology, Jikei University School of Medicine, Tokyo, Japan.
FAU - Egawa, Shin
AU  - Egawa S
AD  - Department of Urology, Jikei University School of Medicine, Tokyo, Japan.
LA  - eng
SI  - ClinicalTrials.gov/NCT00664456
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20160725
PL  - United States
TA  - Cancer Med
JT  - Cancer medicine
JID - 101595310
RN  - 0 (Androgen Antagonists)
RN  - 0 (Antineoplastic Agents, Hormonal)
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Radioisotopes)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Androgen Antagonists/administration & dosage/adverse effects/*therapeutic use
MH  - Antineoplastic Agents, Hormonal/administration & dosage/adverse 
      effects/*therapeutic use
MH  - Biomarkers, Tumor
MH  - *Brachytherapy/adverse effects/methods
MH  - Combined Modality Therapy
MH  - Follow-Up Studies
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Grading
MH  - Neoplasm Staging
MH  - Prostatic Neoplasms/*diagnosis/mortality/*therapy
MH  - Radioisotopes/administration & dosage
MH  - Radiotherapy Dosage
MH  - Retrospective Studies
MH  - Survival Analysis
MH  - Tomography, X-Ray Computed
MH  - Treatment Outcome
PMC - PMC5055153
OTO - NOTNLM
OT  - Androgen deprivation therapy
OT  - brachytherapy
OT  - dose-response
OT  - prostate cancer
EDAT- 2016/07/28 06:00
MHDA- 2017/11/29 06:00
PMCR- 2016/07/25
CRDT- 2016/07/27 06:00
PHST- 2015/12/21 00:00 [received]
PHST- 2016/05/25 00:00 [revised]
PHST- 2016/06/14 00:00 [accepted]
PHST- 2016/07/27 06:00 [entrez]
PHST- 2016/07/28 06:00 [pubmed]
PHST- 2017/11/29 06:00 [medline]
PHST- 2016/07/25 00:00 [pmc-release]
AID - CAM4820 [pii]
AID - 10.1002/cam4.820 [doi]
PST - ppublish
SO  - Cancer Med. 2016 Sep;5(9):2314-22. doi: 10.1002/cam4.820. Epub 2016 Jul 25.